Founder, President, CEO
Jeffrey H. Price, MD, PhD
Dr. Price received his MD from Loma Linda University and his PhD in bioengineering from UC San Diego. He began his career in high throughput microscopy research in 1987, which lead him to found his first company, Q3DM Inc in 1999 and was sold to Beckman Coulter Inc in 2003. Dr. Price is also an Associate Professor at The Sanford-Burnham Medical Research Institute where he trains graduate students from Bioengineering at UC San Diego.
Vice President of Biology
Patrick M. McDonough, PhD
Dr. McDonough received his Ph.D. in Marine Biology from Scripps Institution of Oceanography, and has held appointments in cell and molecular biology at the University of California, San Diego Medical School, and San Diego State University Department of Biology. Dr. McDonough's expertise is focused in subcellular structure and dynamics of cardiac muscle, skeletal muscle, fibroblast, astrocytoma, nerve, kidney, and cervical tumor cells using fluorescence microscopy.
Vice President of Commercial Operations
Martin Stuart, PhD
Dr. Stuart is a serial entrepreneur who has enjoyed more than 25 years of commercial success introducing new and complex technologies to the Life Science and Healthcare markets. Operating largely at the intersection of science and business, Dr. Stuart’s forte is transforming technology driven companies into market driven organizations with solid business acumen. He has taken two companies from inception to $50+M and ultimately exit through acquisition or public markets. Dr. Stuart spent 7+ years with Aperio Technologies where he was responsible for building commercial operations including sales, marketing and services. These initiatives coupled with solid, sustained, commercial growth propelled Aperio to be the undisputed leader in the global digital pathology market. Aperio was acquired by Leica Biosystems, a Danaher Company. Dr. Stuart was awarded a Ph.D. from The University College of North Wales for his work on Ultra High Resolution Imaging of Langmuir Blodgett films and a B.Sc. in Physics from CNAA, London, England.
Ross Whittaker, PhD, MBA
Dr. Whittaker received his Ph.D. from the University of California, San Diego via the San Diego State University/University of California, San Diego Joint Doctoral program. Dr. Whittaker's expertise is in the area of signal transduction, with an emphasis on cardiac signaling pathways activated during acute ischemic stress, such as during a heart attack. Dr. Whittaker also holds an M.B.A. from the San Diego State University School of Business.
Director of Software Engineering
Randy Ingermanson, PhD
Randy holds a Ph.D. in theoretical physics from UC Berkeley and has nearly twenty years experience in scientific software development. He has directed a number of complex software projects in industrial physics, applied engineering, and bioscience. Randy has special expertise in numerical solution of large numbers of nonlinear equations, in object-oriented analysis and design, and in image-processing applications. He is also a multi-published author, with one nonfiction book, six novels, and about a dozen writing awards to his credit.
Director of Finance
Michael Geremia, MBA
Michael received his Bachelors of Science in Finance and MBA from San Diego State University. He is the founder of two start-up ventures, one of which successfully licensed its product to to a multinational consumer product company. Prior to his recent entrepreneurial ventures Mike served as Director of Finance and Corporate Controller for a $70 million organization where he strategically directed all aspects of accounting and finance to develop core strategy and maximize profitability for the organization.
Board of Directors
Mark McWilliams, MSME
Mark currently serves as CEO of Medipacs, an early stage medical device firm bringing to market a series of miniature, disposable infusion pumps. Prior to Medipacs, Mark was Director of Cell Imaging and Analysis at Beckman Coulter after the sale of Q3DM to Beckman in December 2003. He was Chief Executive Officer and Director of Q3DM, a life -sciences startup that brought to market a high-speed imaging and analysis system for life science research and diagnostics. Prior to Q3DM, Mark was founder and COO of Medication Delivery Devices (MDD), an alternate care infusion systems company that was acquired by Baxter Healthcare in 1996. Mr. McWilliams served as a VP of Research and Development at Baxter Healthcare for three years following the sale of MDD. Prior to MDD, he served as Product Development Manager at the founding of Block Medical where he was responsible for bringing the company's first two FDA approved products rapidly to market. Block was sold to Hillenbrand Industries in 1991. Mark serves on the board of directors of Spectra Science, a cancer diagnostic instrument company. He earned his MSME from the Massachusetts Institute of Technology, his BSME from Northeastern University and holds eight utility patents.
Paul J. Dostart, CPA, J.D., LL.M.
Mr. Dostart serves as Vala’s Executive Vice President. Mr.Dostart co-founded Q3DM Inc and has helped several of his law clients join the Inc. 500 list of America ’s most rapidly growing closely held businesses. Mr. Dostart is active in governance and regulatory issues affecting San Diego ’s biotechnology research community.
John K. Westwick, PhD
Dr. Westwick is the President and CEO of Odyssey Thera, Inc., where he has led research and development efforts since 2002. Dr. Westwick worked previously at Celgene Corp. and Signal Pharmaceuticals. He holds a B.A. degree in Biology from the University of California at San Diego, and a Ph.D. in Molecular Pathology from the UC San Diego School of Medicine. Post-doctoral studies in Medicine and Pharmacology were performed at the University of North Carolina, Chapel Hill School of Medicine, and he was subsequently named the Lineberger Fellow at the UNC Comprehensive Cancer Center. Dr. Westwick’s scientific and biotech career spans 27 years, and he has contributed to technology and drug development programs resulting in multiple drugs that are currently marketed and in human clinical trials. He has presented this work to over 200 international scientific conferences, pharmaceutical and biotech companies, and published more than 60 scientific articles and patents. In addition to his work at Odyssey and Vala, Dr. Westwick serves on the Scientific Advisory Board of Visionary Pharmaceuticals.
Scientific Advisory Board
Mark Mercola, Ph.D., Professor, Sanford-Burnham Medical Research Institute
Michael A. Mancini, Ph.D., Associate Professor, Baylor College of Medicine
Corporate and Securities Counsel
Patrick Valentino, Corporate Counsel Group, LLC
Terrance A. Meador, INCAPLAW, LLC
Squar, Milner, Peterson, Miranda & Williamson, LLP